Check-Cap is redefining colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free test to detect precancerous polyps and enable early intervention and cancer prevention. The company’s disruptive capsule-based screening technology aims to drastically increase screening adherence worldwide and help millions of people stay healthy through preventive CRC screening. The technology has been evaluated in a pilot study in the U.S. and has received regulatory approval for marketing in the EU and Israel. Data from clinical trials showed promising results, including safety, high patient compliance, and high sensitivity at detecting precancerous polyps when the technology was compared to the FIT test. Check-Cap plans to initiate a pivotal study of the C-Scan in the U.S. by the end of Q1 2022.
The C-Scan System utilizes an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is patient-friendly and requires no preparation or sedation, allowing the patients to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.